Research / CL / Fundamental state Inspectable configuration
State dimensions Filing 0000021665-26-000048 General Corporate
Capex intensity 20th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.capex_revenue_ratio
2.50% · OPTIONAL · VALID
Operating cash generation 80th Own-history percentile · N=20
Evidence method Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
21.81% · OPTIONAL · VALID
Share-count growth 15th Own-history percentile · N=20
Evidence method Yoy · gp.fundamentals.shares_outstanding
-1.38% · CORE · VALID
Revenue growth 45th Own-history percentile · N=20
Evidence method Yoy · gp.fundamentals.revenue
4.64% · CORE · VALID
Inventory pressure 55th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.inventory_revenue_ratio
40.64% · OPTIONAL · VALID
Gross margin 70th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.gross_margin
60.22% · CORE · VALID
Operating margin 45th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.operating_margin
20.26% · CORE · VALID
SBC intensity 80th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.sbc_revenue_ratio
1.17% · OPTIONAL · VALID
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 27 states Self-history eligible
Mar 31, 2019 0/9 normalized Level 3 Jun 30, 2019 0/9 normalized Level 3 Sep 30, 2019 7/9 normalized Level 3 Dec 31, 2019 7/9 normalized Level 3 Mar 31, 2020 7/9 normalized Level 3 Jun 30, 2020 8/9 normalized Level 3 Sep 30, 2020 8/9 normalized Level 3 Dec 31, 2020 8/9 normalized Level 3 Mar 31, 2021 8/9 normalized Level 3 Jun 30, 2021 9/9 normalized Level 3 Sep 30, 2021 9/9 normalized Level 3 Dec 31, 2021 8/9 normalized Level 3 Mar 31, 2022 9/9 normalized Level 3 Jun 30, 2022 9/9 normalized Level 3 Sep 30, 2022 9/9 normalized Level 3 Dec 31, 2022 8/9 normalized Level 3 Mar 31, 2023 9/9 normalized Level 3 Jun 30, 2023 9/9 normalized Level 3 Sep 30, 2023 9/9 normalized Level 3 Sep 30, 2026 8/8 normalized Level 4 Period transition
What moved in the state? Capex Intensity Increased
Previous 2.39%
Current 2.50%
Delta 0.11% Cash Generation Increased
Previous 18.56%
Current 21.81%
Delta 3.25% Dilution Decreased
Previous -1.37%
Current -1.38%
Delta -0.02% Growth Decreased
Previous 4.91%
Current 4.64%
Delta -0.27% Inventory Pressure Decreased
Previous 40.68%
Current 40.64%
Delta -0.04% Margin Decreased
Previous 61.48%
Current 60.22%
Delta -1.26% Profitability Increased
Previous 18.95%
Current 20.26%
Delta 1.31% Sbc Intensity Increased
Previous 0.71%
Current 1.17%
Delta 0.46% Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Jun 30, 2026
Similarity 80%
Compared 8 dimensions
Coverage 100% Growth 5.0 · Margin 30.0 · Dilution 0.0 · Profitability 30.0 · Sbc Intensity 20.0 · Capex Intensity 10.0 · Cash Generation 30.0 · Inventory Pressure 5.0 Jun 30, 2024
Similarity 79%
Compared 8 dimensions
Coverage 100% Growth 10.0 · Margin 10.0 · Dilution 26.2 · Profitability 5.0 · Sbc Intensity 45.0 · Capex Intensity 10.0 · Cash Generation 20.0 · Inventory Pressure 0.0 Sep 30, 2025
Similarity 79%
Compared 8 dimensions
Coverage 100% Growth 25.0 · Margin 30.0 · Dilution 5.0 · Profitability 10.0 · Sbc Intensity 20.0 · Capex Intensity 30.0 · Cash Generation 20.0 · Inventory Pressure 10.0 Dec 31, 2024
Similarity 77%
Compared 7 dimensions
Coverage 88% Growth 15.0 · Margin 0.0 · Profitability 5.0 · Sbc Intensity 20.0 · Capex Intensity 30.0 · Cash Generation 15.0 · Inventory Pressure 45.0 Dec 31, 2019
Similarity 73%
Compared 6 dimensions
Coverage 75% Margin 14.4 · Profitability 22.8 · Sbc Intensity 46.7 · Capex Intensity 13.3 · Cash Generation 13.3 · Inventory Pressure 32.8 Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.